We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
- Authors
Ketterer, N; Coiffier, B; Thieblemont, C; Fermé, C; Brière, J; Casasnovas, O; Bologna, S; Christian, B; Connerotte, T; Récher, C; Bordessoule, D; Fruchart, C; Delarue, R; Bonnet, C; Morschhauser, F; Anglaret, B; Soussain, C; Fabiani, B; Tilly, H; Haioun, C
- Abstract
The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Vol 24, Issue 4, p1032
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mds600